CALL/MODERNA/220/0.1/21.06.24 | Real-time BOERSE MUENCHEN 09:55:12 06/06/2024 pm IST | ||
| 0.024 EUR | +41.18% |
|
| Current month | -55.26% | ||
| 1 month | +142.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 06/24/06 | 0.024 | +41.18% |
| 05/24/05 | 0.017 | -15.00% |
| 04/24/04 | 0.02 | -39.39% |
| 03/24/03 | 0.033 | -13.16% |
| 31/24/31 | 0.038 | +52.00% |
Real-time BOERSE MUENCHEN
Last update June 06, 2024 at 09:55 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Goldman Sachs |
| WKN | GP0BQ4 |
| ISIN | DE000GP0BQ41 |
| Date issued | 08/03/2023 |
| Strike | 220 $ |
| Maturity | 21/06/2024 (15 Days) |
| Parity | 10 : 1 |
| Emission price | 1.22 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.87 € |
|---|---|
| Lowest since issue | 0.003 € |
| Spread | 0.03 € |
| Spread % | 57.69% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
154.8
USD
Average target price
142.8
USD
Spread / Average Target
-7.77%
- Stock Market
- Warrants
- Warrant
